Hjem › Lungecancer › Illinois › Joliet
Lungecancer kliniske forsøg i Joliet, IL
12 studier for Lungecancer søger deltagere på steder i og omkring Joliet (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi væk
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi væk
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi væk
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi væk
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
RekruttererFase 2
- Hope and Healing Clinical Research, New Lenox · 6 mi væk
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi væk
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RekruttererFase 2
- Hope and Healing Clinical Research, New Lenox · 6 mi væk
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekruttererFase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi væk
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RekruttererFase 1/2
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi væk
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi væk
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- University of Chicago, New Lenox · 6 mi væk
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi væk
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi væk
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi væk
Lungecancer forsøg i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Washington, DC41 studier
- Arlington, VA41 studier
- Chicago, IL41 studier
- Nashville, TN40 studier
- Baltimore, MD40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Joliet
- Ikke-småcellet lungecancer12 studier
- Metastatisk cancer7 studier
- Blærecancer7 studier
- Pladecellekræft i hoved og hals6 studier
- Prostatakræft5 studier
- Hypofarynxcancer5 studier
- Larynxcancer5 studier
- Oral Cancer5 studier
- Akut myeloid leukæmi5 studier
- Brystkræft4 studier
- Tyktarmskræft4 studier
- Nyrekancer (renocellulært karcinom)4 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.